NEEDHAM, Mass., & PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Tyrogenex, focused on next-gen targeted therapeutics for ophthalmology, presented data from its phase 1 safety study of orally-administered X-82 in patients for wet AMD at EURETINA Congress.
| < Prev | Next > |
|---|
